Benchmark analyst Josh Sullivan maintains Ultralife (NASDAQ:ULBI) with a Buy and raises the price target from $12 to $13.
- Headlines
- Benchmark Maintains Buy on Ultralife, Raises Price Target to $13
Benchmark Maintains Buy on Ultralife, Raises Price Target to $13
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.
Related Stocks Related Stocks
Symbol Mini Chart Latest Price
Unlock the Full List
Latest
16:19
Mislabeling of pet food ingredients? Nanh District, Xingtai City: Production suspended, investigation and rectification underway.
16:18
The private equity giant CVC has proposed to take the German medical software provider CompuGroup Medical private at a price of 22 euros per share.
16:17
hello group: Net revenue for the third quarter is 2.67 billion yuan.
MOMO+2.27%